Trellus Health
plc
("Trellus
Health" or the "Company")
Notice of
Results
Investor
Presentation
LONDON, U.K. AND NEW YORK, U.S. (16 April 2024).
Trellus Health plc (AIM: TRLS),
a health services company delivering innovative,
scientifically validated programs and technologies that facilitate
the comprehensive management of chronic conditions, improving
health outcomes whilst managing costs of care, announces that it
expects to report its final results for the year ended 31 December
2023 on Tuesday 23 April 2024.
Investor Presentation
Dr. Marla Dubinsky, CEO and
Co-Founder, and Joy Bessenger, Chief Financial
Officer, will provide a live presentation relating to
the final results via Investor Meet Company on Wednesday
24 April 2024 at 4.00pm (BST).
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Trellus Health
plc via:
https://www.investormeetcompany.com/trellus-health-plc/register-investor
Investors who already follow Trellus
Health plc on the Investor Meet Company platform will automatically
be invited.
For
further information please contact:
|
Trellus Health plc
|
https://trellushealth.com/
|
|
Dr. Marla Dubinsky, CEO and
Co-Founder
|
Via Walbrook
PR
|
|
Dr. Daniel Mahony,
Chairman
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and
Broker)
|
Tel: +44 (0)20 7496
3000
|
|
Aubrey Powell / Jen
Boorer
|
|
|
|
|
|
Walbrook PR
|
Tel: +44 (0)20 7933
8780 or trellus@walbrookpr.com
|
|
Paul McManus / Sam Allen / Phillip
Marriage
|
Mob: +44
(0)7980 541 893 / (0)7502 558 258/ (0)7867
984 082
|
|
|
| |
About Trellus Health plc (www.trellushealth.com)
Trellus Health (AIM: TRLS) is a
health services company providing value-based innovative solutions
and services for chronic condition management that prioritises
improved outcomes and member experiences while managing costs of
care.
Trellus Health integrates its
proprietary resilience-based methodology with the technology,
tools, and expert coaching and educator team to deliver Trellus
Elevate™, a whole-person technology-enhanced experience that meets
each individual's unique needs and empowers them to master their
physical and emotional health. Trellus Elevate's™ clinically proven
solutions result in relieving disease burden, building
self-management skills and promoting positive health behaviours
that improve outcomes and enables thriving in the face of a chronic
condition.
The Company's proven whole person
approach recognises the interconnectedness of various aspects of a
person's life and aims to address the whole spectrum of factors
that influence behaviour, to promote comprehensive well-being and
human flourishing in a way that aligns with value-based care.
Trellus Health's approach enables better health outcomes in a
member-centric, personalised and comprehensive holistic
solution.
The Company was founded by Mount
Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD,
both experts at treating and healing both the physical and
emotional impacts of IBD and have been innovators for whole person
healthcare for a combined 50 years.
The Company is initially focusing on
chronic costly GI conditions that have high mental health burden,
such as inflammatory bowel disease ("IBD") which includes the
chronic incurable conditions of Crohn's Disease and ulcerative
colitis. Given the common emotional and mental health struggles
often experienced by individuals suffering from a variety of
chronic conditions, Trellus Health considers its approach to have
potential utility and demand across many conditions.
The Trellus Elevate™ program
incorporates the GRITT™ methodology and learnings on resilience
from clinical research and practice conducted at the Mount Sinai
IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to
demonstrate meaningful improvements in patient outcomes, 71%
reduction in Emergency Department (A&E) visits, and 94%
reduction in unplanned hospitalisations, which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers and health systems. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health
outcomes1.
Shares in Trellus Health were
admitted to trading on AIM in May 2021, under the ticker TRLS. For
more information on Trellus Health, visit:
www.trellushealth.com
1 Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258